Role of EgIN2 Prolyl Hydroxylase in Mammary Tumorigenesis

EgIN2脯氨酰羟化酶在乳腺肿瘤发生中的作用

• 批准号: 7675022
• 负责人: Qing Zhang
• 金额: $ 5.17万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7675022
• 关键词: Biochemical; Breast; Breast Cancer Cell; Breast Cancer Treatment; Breast Carcinoma; Cyclin D1; Cyclins; Data; Development; Down-Regulation; Drug Delivery Systems; Epithelial; Epithelial Cells; Epithelium; Estrogen Receptors; Estrogen receptor positive; Estrogens; Genes; Genetic; Growth; In Vitro; Mammary Neoplasms; Mammary Tumorigenesis; Molecular; Mus; Procollagen-Proline Dioxygenase; Receptor Signaling; Role; Signal Transduction; Testing; Therapeutic; Transcriptional Activation; Woman; cell transformation; in vivo; innovation; malignant breast neoplasm; novel; public health relevance; transcription factor; tumor growth

DESCRIPTION (provided by applicant): One in eight women will suffer breast cancer during their lifetime. About 70% of breast cancer depends on the presence of estrogen to grow, and is classified as Estrogen Receptor (ER) positive and estrogen- dependent. ER regulates the expression of many genes, among which is Cyclin D1. High levels of Cyclin D1 have been observed in over 50% of mammary carcinomas. Downregulation of Cyclin D1 could inhibit breast tumor growth in vivo. Another ER target, EglN2 prolyl hydroxylase, has been found to regulate the expression of Cyclin D1, which places ER upstream of EglN2, and EglN2 upstream of Cyclin D1. In this proposal, I plan to use a combination of genetic and biochemical approaches to understand the role of EglN2 in ER signaling and mammary tumorigenesis. First, I will determine whether EglN2 loss will inhibit breast epithelia cell transformation in vitro. Next, I will introduce EglN2-downregulated breast cancer cells, which I found to slow breast cancer growth in vitro, into mice to test whether they slow down tumor growth in vivo. Lastly, I will study the mechanism by which EglN2 regulates Cyclin D1 expression. Together, these proposed studies describe an innovative way to downregulate Cyclin D1. PUBLIC HEALTH RELEVANCE: The data collected will greatly enrich our understanding of the role of EglN2 in Estrogen Receptor (ER) signaling and mammary tumorigenesis. Therefore, it will facilitate the development of effective drug targeting ER downstream signaling and provide a novel and potential successful therapeutic strategy for breast cancer treatment.

描述（由申请人提供）：八分之一的女性在其一生中会患乳腺癌。约70%的乳腺癌依赖雌激素的存在生长，分为雌激素受体（ER）阳性和雌激素依赖型。内质网调节多种基因的表达，Cyclin D1就是其中之一。在超过50%的乳腺癌中观察到高水平的Cyclin D1。下调Cyclin D1在体内可抑制乳腺肿瘤的生长。另一个内质网靶点EglN2脯氨酸羟化酶被发现调节Cyclin D1的表达，使ER位于EglN2的上游，EglN2位于Cyclin D1的上游。在本提案中，我计划采用遗传和生化相结合的方法来了解EglN2在内质网信号传导和乳腺肿瘤发生中的作用。首先，我将确定EglN2缺失是否会在体外抑制乳腺上皮细胞的转化。接下来，我将把egln2下调的乳腺癌细胞引入到小鼠体内，测试它们是否会减缓肿瘤的生长，我发现egln2下调的乳腺癌细胞在体外可以减缓乳腺癌的生长。最后，我将研究EglN2调控Cyclin D1表达的机制。总之，这些提出的研究描述了一种下调Cyclin D1的创新方法。公共卫生相关性：收集的数据将极大地丰富我们对EglN2在雌激素受体（ER）信号传导和乳腺肿瘤发生中的作用的理解。因此，它将有助于开发有效的靶向内质网下游信号的药物，并为乳腺癌治疗提供新的和潜在的成功治疗策略。